A variety of tumor cell-based efficacy assays are available for the development of anti-cancer drugs. At Alfa Cytology, with advanced 3D tumor spheroid models, we help our clients with 3D tumor spheroid assay, soft agar assay, and angiogenesis assay for bladder cancer drug development.
Bladder cancer is a complex three-dimensional (3D) tumor structure composed of specific tissues and cells. Traditional 2D cell culture models, although valuable in many aspects, fail to fully recapitulate the complex microenvironment and interactions between cells. 3D cell-based assays have gained immense popularity in recent years due to their ability to provide a more physiologically relevant platform for studying cancer biology.
Fig 1. The main characteristics of 3D spheroids that are crucial for their application in the screening of anticancer therapeutics. (Costa E.C., et al. 2016)
By incorporating three-dimensional architecture, cell-cell interactions, and the extracellular matrix (ECM), these assays offer a more accurate representation of tumor growth, invasion, and response to therapeutic agents.
At Alfa Cytology, we are committed to providing cutting-edge 3D tumor model modelling services to support bladder cancer research and drug discovery. Our 3D cell-based assays provide a reliable, standardized and high-throughput platform for studying bladder cancer biology and anti-cancer drug development.
Here are some of the key services we offer:
Our Services | Descriptions |
---|---|
3D Tumor Spheroid Assay |
|
Soft Agar Assay |
|
Angiogenesis Assay |
|
At Alfa Cytology, we understand the critical importance of advanced technologies in advancing bladder cancer research. Our 3D cell-based assays provide a powerful and comprehensive platform for studying bladder cancer biology, identifying potential therapeutic targets, and evaluating drug efficacy. If you have any inquiries or would like to learn more about our services for bladder cancer research, please don't hesitate to contact us.
Reference
Alfa Cytology is dedicated to drug development and preclinical services for bladder cancer.